Prenuvo pioneered the use of advanced MRI using AI to proactively screen for cancer and disease in under one hour. Based on 10 years of clinical research, Prenuvo can detect solid tumors at Stage 1 and over 500 other health conditions, leading to much better health outcomes for its patients. Prenuvo is on a mission to allow consumers to take charge of their health by moving from reactive to proactive.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/18/22 | $70,000,000 | Series A |
Anne Wojcicki Cindy Crawford Felicis Ventures  Rande Gerber Steel Perlot Timothy Springer Tony Fadell | undisclosed |
